Background: Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome MET-based resistance to EGFR-TKIs.
Objective: To investigate the safety and tolerability of savolitinib in Japanese patients with advanced solid malignancies.
Patients And Methods: In Part C of the phase Ib, multi-arm, open-label, multicenter TATTON study, two cohorts of Japanese adult patients were evaluated across six study centers in Japan. Patients with advanced solid malignancies received oral savolitinib monotherapy 400 mg once daily (qd), escalating to 600 mg; patients with advanced EGFR mutation-positive (EGFRm) non-small-cell lung carcinoma (NSCLC) who progressed on prior EGFR-TKI received oral osimertinib 80 mg+savolitinib 300/400/600 mg qd combination therapy. Primary endpoints: safety/tolerability of savolitinib±osimertinib, and maximum tolerated dose(s) (MTD) definition.
Results: Seventeen patients received monotherapy; 12 received combination. Dose-limiting toxicities (DLTs): with monotherapy, 400 mg, none reported; 600 mg, n = 3/9 evaluable patients (33%) reported DLTs (grade 3 and 4 alanine aminotransferase and aspartate transaminase increased, and grade 4 drug-induced liver injury). With combination: 400 mg, 1/6 (17%) reported DLTs (grade 2 fatigue, nausea, and myalgia); 300 mg, none reported; 600 mg, 3/4 (75%) reported DLTs (grade 2 pyrexia, grade 3 skin reaction, and anaphylactic shock). Grade ≥3 adverse events were reported in 41% of patients receiving monotherapy and 33% receiving combination. TATTON is no longer recruiting patients.
Conclusions: The MTD of savolitinib was 400 mg qd in both cohorts. Data demonstrate an acceptable safety profile for savolitinib alone, or with osimertinib.
Trial Registration: Clinicaltrials.gov; NCT02143466; 21 May 2014.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105224 | PMC |
| http://dx.doi.org/10.1007/s11523-021-00806-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Review of Outcomes After Peripheral Nerve Transfers for Motor Nerve Injury in the Upper Extremity.
JBJS Rev
November 2024
Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine, Anschutz Medical Center, Aurora, Colorado.
Background: Modern nerve-to-nerve transfers are a significant advancement in peripheral nerve surgery. Nerve transfers involve transferring donor nerves or branches to recipient nerves close to the motor end unit, leading to earlier reinnervation and preservation of the musculotendinous units in proximal nerve injuries. After nerve reinnervation, function may be superior to traditional tendon transfer techniques in terms of strength and independent motion.
View Article and Find Full Text PDFEditorial Comment: Advancing Radiopharmaceutical Therapy Through Patient-Specific Dosimetry.
AJR Am J Roentgenol
January 2025
Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Exploring Denosumab in the Treatment of Giant Cell Tumors: Clinical Evidence and Controversies.
J Craniofac Surg
November 2024
Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL.
Giant cell tumors (GCTs) are benign but locally aggressive bone neoplasms that primarily affect skeletally mature individuals. They are characterized by a tendency for recurrence and being associated with significant morbidity. Traditional treatment has focused on surgical resection; however, the role of medical therapies, such as Denosumab, a bone anti-resorptive drug, which has been Food and Drug Administration (FDA)-approved for unresectable GCTs since 2013, recently has gained prominence.
View Article and Find Full Text PDFEvidence of organizational support in hospitals in the context of the COVID-19 pandemic: scoping review.
Rev Gaucha Enferm
January 2025
Universidade de São Paulo, Escola de Enfermagem, Programa de Pós-Graduação em Gerenciamento em Enfermagem, São Paulo, São Paulo, Brasil.
Objective: To map evidence of organizational support for healthcare professionals who worked in hospitals during the pandemic.
Method: This is a scoping review, based on the framework established by Joanna Briggs Institute and the PRISMA-ScR protocol, registered in the Open Science Framework, under DOI: 10.17605/OSF.
The (dis)continuity of breastfeeding care in prison: perception of health professionals and managers.
Rev Gaucha Enferm
January 2025
Universidade Federal do Pará. Belém. Pará. Brasil.
Objective: to describe the perception of health professionals and managers in the prison system regarding the continuity of breastfeeding care for lactating women deprived of liberty.
Method: descriptive-exploratory research, qualitative approach, developed in a prison unit in Rio de Janeiro from December 2022 to January 2023. Interviewees: five health professionals and two managers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!